arrow
C

Christophe Piketty

University of London
H指数:38
被引数:5,708

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

奈莫珠单抗治疗结节性痒疹长达100周: 奥林匹亚LTE中期分析

2025-12-010
OAAI
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study

纳莫利zumab治疗特应性皮炎长达2年的开放标签扩展研究的安全性与有效性

2025-10-130
OAAI
Patients' Experiences of Atopic Dermatitis and Nemolizumab Treatment: An In-Trial Interview Study Embedded in a Phase 3 Clinical Trial (ARCADIA)

特应性皮炎及nemolizumab治疗的患者体验:一项嵌入在3期临床试验(ARCAEDIA)中的试验内访谈研究

2025-05-130
OAAI
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis The OLYMPIA 1 Randomized Clinical Phase 3 Trial

中重度结节性痒疹患者中Nemolizumab的疗效与安全性:OLYMPIA 1随机临床试验(III期)

2025-02-014
PRE
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials
LANCET
IF88.5
2024-08-013
PRE
Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab
2024-01-0113
OAAI